Clinical Trials Logo

Clinical Depression clinical trials

View clinical trials related to Clinical Depression.

Filter by:
  • None
  • Page 1

NCT ID: NCT06005194 Recruiting - Clinical trials for Depressive Disorder, Major

InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI

Start date: November 14, 2023
Phase: N/A
Study type: Interventional

The purpose of this randomized controlled trial is to evaluate whether the InMotion intervention, delivered via telehealth (using a HIPAA-compliant video platform or phone), which uses evidence-based behavioral and motivational counseling to increase daily physical activity, is an effective treatment for Major Depressive Disorder (MDD) for people who are at least one year out from sustaining a traumatic brain injury (TBI). The first aim is to compare the efficacy of the InMotion intervention to the waitlist control (WLC) condition on measures of depression severity and associated conditions in under-active adults with TBI and MDD. For the second aim the investigators plan to identify possible moderators of exercise treatment effects. The third aim will examine possible mediators of treatment outcome. In addition, the weekly dose of exercise, the extent to which exercise generates positive affect, and engagement in enjoyable or meaningful aspects of life will be explored.

NCT ID: NCT05685758 Completed - Depression Clinical Trials

A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model

FTP
Start date: November 3, 2022
Phase: N/A
Study type: Interventional

The study is a randomized controlled treatment study comparing changes in depressive symptoms over 8 weeks between individuals with Major Depressive Disorder (MDD) who have access to an FTP-based mobile phone application and a control group not engaging with the app. FTP, the process of Facilitating Thought Progression, trains the brain's cognitive thought process to expand, accelerate, and be more creative, to alleviate depressive symptoms.

NCT ID: NCT04496505 Withdrawn - Clinical Depression Clinical Trials

Neuromodulation Device Use in Patients With Major Depressive Disorder

Start date: August 17, 2020
Phase: N/A
Study type: Interventional

Study the neuromodulation device in the treatment of Major Depressive Disorder and associated symptoms. In this study we use the Hamilton Depression Rating Scale (HAM-D), the Quality of Life Scale (QQLS), the Rumination Response Scale (RRS), the Brief Irritability Test (BIT), the Generalized Anxiety Disorder 7 Item Scale (GAD 7), and the Future Orientation Scale (FOS). This study was designed to mirror real life situations, and thus patients are not asked to stop their pharmaceutical treatments. Primary hypothesis for this study is: o Daily use of the device will decrease depressive symptoms as measured by HAM-D. Secondary hypotheses for these study are: - Daily use of the device will increase quality of life as measured by the QQLS. - Daily use of the device will decrease rumination as measured by the RRS. - Daily use of the device will decrease irritability as measured by the BIT. - Daily use of the device will increase future orientation as measured by the FOS. - Daily use of the device will decrease anxiety as measured by the GAD-7.

NCT ID: NCT04322422 Recruiting - Asthma Clinical Trials

Clinical Characteristics and Treatment of Chest Tightness Variant Asthma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Asthma, abbreviation for bronchial asthma, is one of the common chronic airways disease that threatens human health. Typical symptoms of asthma are recurrent wheezing, shortness of breath, chest tightness and cough, usually occurring at night or early morning. However, there are still some patients with only persistent clinical manifestations of chest tightness. Concerned about this group of patients, investigators presented a subgroup of bronchial asthma, namely, chest tightness variant asthma (CTVA). This asthma subgroup usually lacks asthma-specific clinical features such as wheezing, shortness of breath, wheezing, and therefore often misdiagnosed for a long time. However, there is lack of definite treatment strategy for CTVA. In order to further understand the clinical characteristics and treatment of patients with CTVA, investigators conducted a national multicenter randomized control trial(RCT) study that compares inhaled corticosteroid(ICS)/ long-acting beta2-agonist(LABA) + Montelukast with ICS/LABA. Finally, investigators plan to clarify whether ICS/LABA plus Montelukast is more appropriate treatment than only ICS/LABA in CTVA patients.

NCT ID: NCT04211467 Recruiting - Depression Clinical Trials

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records

NCT ID: NCT03489304 Completed - HIV/AIDS Clinical Trials

Zaleplon in HIV Patients With Depression

Start date: April 3, 2014
Phase: Phase 2
Study type: Interventional

In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index (ISI) and Epworth sleepiness scale (ESS).

NCT ID: NCT03237221 Completed - Asthma Clinical Trials

Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma

Start date: March 1, 2015
Phase:
Study type: Observational

Asthma, abbreviation for bronchial asthma, is one of the common chronic airways disease that threatens human health. Typical symptoms of asthma are recurrent wheezing, shortness of breath, chest tightness and cough, usually occurring at night or early morning. However, there are still some patients with only persistent clinical manifestations of chest tightness. Concerned about this group of patients, we presented a subgroup of bronchial asthma, namely, chest tightness variant asthma (CTVA). This asthma subgroup usually lacks asthma-specific clinical features such as wheezing, shortness of breath, wheezing, and therefore often misdiagnosed for a long time. In order to further understand the clinical characteristics, pathogenesis, and prognosis of patients with CTVA, we conducted a national multicenter observation study to further understand CTVA. Finally, we plan to clarify whether CTVA is a relatively independent asthma phenotype. Meanwhile, reducing misdiagnosis and perform an appropriate treatment of CTVA.

NCT ID: NCT01977326 Completed - Clinical trials for Postpartum Depression

Task Sharing Counseling Intervention by Community Health Workers for Prenatal Depression in South Africa

AFFIRM-SA
Start date: October 2013
Phase: N/A
Study type: Interventional

The objective of this randomised controlled trial (RCT) is to determine the effectiveness and cost-effectiveness of a task sharing counseling intervention for maternal depression in South Africa(i.e. provided by non-specialist health workers)

NCT ID: NCT01763216 Completed - Depressive Symptoms Clinical Trials

Improving Mood in Assisted Living Settings

Start date: February 2013
Phase: N/A
Study type: Interventional

Late-life depression levels are escalating, and include 24% of all tenants of Assisted Living (AL) settings. A promising, novel intervention is a computerized visual speed of processing training program known as Road Tour. Road Tour has been show to reduce depressive symptom levels and the risk of onset of clinical depression in community dwelling older adults. The investigators hypothesize that similar benefits will accrue to residents in AL settings. To evaluate this the investigators will use a two-arm, parallel, randomized controlled trial (RCT) comparing Road Tour training to attention control using computerized crossword puzzles among 370 adults 55 years old or older who reside in 15-30 AL settings that are partnering with the investigators. The investigators hypothesize that Road Tour participants will have improved cognitive processing speed, lower levels of depressive symptoms, lower likelihood of the onset of clinical depression, less anxiety, lower levels of pain symptoms, and better health-related quality of life. These outcomes will be assessed at baseline, post-training, six months, and one year.